Peptide education
PT-141
Bremelanotide · Vyleesi · BMT · Melanocortin receptor agonist
PT-141 is the research code name that stuck to bremelanotide, a cyclic peptide from the melanotan research lineage that acts on sexual desire through the brain rather than on blood flow. It is the rare internet peptide with a genuine FDA approval behind it: as Vyleesi, a 1.75 mg autoinjector, for acquired, generalized hypoactive sexual desire disorder in premenopausal women. The approval has hard edges: no indication for men or postmenopausal women, no performance claim, no proven gain in satisfying sexual events, and no coverage for the vials and sprays sold under the PT-141 name.
Bremelanotide is a rare case where the peptide actually went through phase 3: Vyleesi improved desire and distress scores in premenopausal women with acquired, generalized HSDD, though it never beat placebo on satisfying sexual events. The male evidence is a handful of older intranasal studies with no approval behind them, and the largest one now carries an expression of concern.
Overview
Quick answer
PT-141, Vyleesi, bremelanotide, Melanotan-2, afamelanotide, and ordinary "libido peptide" marketing are often mixed together online. Vyleesi is a regulated 1.75 mg subcutaneous autoinjector with a narrow label. Compounded vials, nasal products, oral products, tanning peptides, and gray-market products raise different identity, sterility, dose, oversight, and safety questions.
What is PT-141?
PT-141 is bremelanotide, a cyclic seven-amino-acid melanocortin agonist descended from the same research line as Melanotan-2. Where MT-2 stayed a gray-market tanning product, this branch was developed as a drug and approved in 2019 as Vyleesi, a single-dose autoinjector.
What is it actually approved for?
Acquired, generalized hypoactive sexual desire disorder in premenopausal women, and only when the low desire causes marked distress or relationship difficulty and is not explained by another condition, a relationship problem, or a medication. The label is explicit about the exclusions: not for men, not for postmenopausal women, and not to enhance sexual performance.
What doses and schedules show up in the label and trials?
1.75 mg under the skin at least 45 minutes before anticipated sexual activity, at most one dose in 24 hours, no more than 8 doses per month, and stop after 8 weeks if symptoms do not improve. In the phase 3 trials, most participants used it only two or three times a month.
Does it work for men, bodybuilding, or generic libido?
For men there is real but dated evidence: intranasal PT-141 produced measurable erectile responses in controlled studies from 2004 and 2005, including a small crossover where 7.5 mg plus low-dose sildenafil outperformed sildenafil alone. A larger 2008 trial in sildenafil nonresponders also reported benefit, but that paper now carries an expression of concern. No male product was ever approved, and nothing in this record touches bodybuilding, mood, tanning, or generic libido-peptide marketing.
What is the product-substitution risk?
Two separate problems get conflated under the PT-141 name. The first is pharmacology: the label reports nausea in 40% of patients, blood pressure rises briefly after each dose, and the drug is contraindicated in uncontrolled hypertension or known cardiovascular disease. The second is supply: Vyleesi is a sterile fixed-dose autoinjector, and a research vial, nasal spray, or compounded product inherits none of its manufacturing, dose, or monitoring guarantees.
Reported practice
Commonly reported protocol
Community as-needed protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
DailyMed describes Vyleesi as a melanocortin receptor agonist for premenopausal women with acquired, generalized HSDD and explicitly limits broader use in men, postmenopausal women, and sexual-performance enhancement.
The labeled product is a 1.75 mg / 0.3 mL single-dose autoinjector used subcutaneously at least 45 minutes before anticipated sexual activity, with limits around repeat and monthly dosing.
Two 24-week randomized trials in premenopausal women with acquired, generalized HSDD found statistically significant improvement in FSFI Desire and FSDS-DAO distress scores compared with placebo.
The label reports no significant difference from placebo for the change in number of satisfying sexual events, an important reminder that the approval is not a blanket sexual-performance claim.
Early double-blind studies tested intranasal PT-141 in healthy men and men with erectile dysfunction. Erectile response was significant versus placebo at doses above 7 mg in the 2004 report, with onset at about 30 minutes; a later small crossover study found greater response when PT-141 was added to low-dose sildenafil.
Vyleesi data belong to a specific approved sterile autoinjector. They do not verify compounded, research-market, intranasal, oral, or melanotan-family products.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| PT-141 treats acquired, generalized HSDD in premenopausal women. | This is the best-supported claim. The FDA label, approval sources, and RECONNECT phase 3 program support bremelanotide/Vyleesi for the labeled HSDD population, with desire and distress endpoints rather than a broad sexual-performance endpoint. | Bremelanotide activates melanocortin receptor subtypes. The label notes that MC4R-expressing neurons are present in many areas of the central nervous system, while also stating that the exact way Vyleesi improves HSDD is unknown. | Online PT-141 discussion often reduces the label to "libido peptide." That phrase misses the label's narrower population, endpoint, and product controls. | Strong when the wording stays tied to Vyleesi, acquired generalized HSDD, premenopausal women, and the studied endpoints. |
| PT-141 improves sexual desire and distress. | In the label summary of the phase 3 trials, Vyleesi improved FSFI Desire Domain score and reduced distress from low desire on FSDS-DAO Question 13 compared with placebo at the end of the 24-week double-blind period. | The melanocortin pathway plausibly connects to central sexual-desire signaling, but mechanism alone does not explain who benefits or how large the effect will be. | Personal-use reports often focus on arousal, timing, nausea, flushing, or whether the effect felt worth it. The labeled HSDD endpoint set is narrower: desire and distress in the studied population. | Best limited to the studied HSDD population and endpoints. That does not make it a guaranteed arousal, orgasm, relationship, or performance effect. |
| PT-141 enhances sexual performance. | The label directly says Vyleesi is not indicated to enhance sexual performance, and the female HSDD trials did not show a significant difference from placebo in satisfying sexual events. That does not erase the older male record: controlled intranasal studies measured erectile response and reported positive signals in healthy men and men with erectile dysfunction. Erectile response in those studies is narrower than a general claim about libido or sexual performance. | Sexual desire, distress, arousal, erection, orgasm, and event frequency are different outcomes. Melanocortin receptor activity does not turn them into one performance claim. | Male-performance and libido marketing commonly uses the PT-141 name, but the Vyleesi label and trial materials are centered on HSDD, not male-performance marketing. | There is direct older human evidence for intranasal erectile-response effects in men, but not a current approval or a basis for a broad performance-enhancement claim. |
| PT-141 is for men. | The Vyleesi label says it is not indicated for HSDD in men, but older controlled trials did directly study intranasal PT-141 for erectile function. A 2004 double-blind placebo-controlled report found significant erectile response at doses above 7 mg in healthy men and Viagra-responsive men with mild-to-moderate erectile dysfunction, with onset at about 30 minutes. A 19-person crossover study reported greater erectile response with 7.5 mg intranasal PT-141 plus 25 mg sildenafil than with sildenafil alone. A separate sildenafil-nonresponder trial reported benefit with 10 mg intranasal bremelanotide, but that publication carries an expression of concern. | Melanocortin signaling can affect sexual-function biology, and older melanocortin-family research helps explain why male claims exist. That does not make Vyleesi an approved male-use product. | Male libido and erectile-function discussion is common in peptide forums, clinics, and gray-market marketing. Those discussions may point to real older trials, but they often detach the findings from the studied intranasal formulation, dose, population, endpoint, and research-era product. | PT-141 has direct controlled male erectile-function evidence, but no current male approval. The older intranasal findings do not prove that a compounded injection, current nasal spray, or gray-market product is equivalent to the study products. |
| PT-141 is a bodybuilding, wellness, mood, or tanning peptide. | PT-141's strong human data are for the Vyleesi HSDD product. They do not cover bodybuilding, wellness optimization, mood enhancement, tanning, fat loss, or physique outcomes. | Melanocortin biology overlaps with pigmentation and central signaling, which explains why PT-141 gets pulled into melanotan and wellness conversations. Overlap in receptor biology does not make the products or claims interchangeable. | Bodybuilding and wellness discussion usually appears as market language, personal-use reporting, or product substitution, not as FDA-reviewed Vyleesi evidence. | People will see PT-141 in those conversations, but Vyleesi evidence does not show those benefits. |
| A PT-141 vial, nasal spray, or oral product is equivalent to Vyleesi. | Vyleesi is a sterile, clear 1.75 mg / 0.3 mL single-dose autoinjector. Its trials and label do not verify the identity, potency, sterility, absorption, storage, or adverse-event systems of other products. | Product equivalence is a manufacturing and formulation question, not only a receptor question. | Gray-market listings may use the PT-141 or bremelanotide name while changing route, concentration, packaging, and handling. Those changes can change the actual exposure and risk. | Vyleesi evidence stays with the autoinjector, route, dose, storage, and adverse-event system described in the label. |
Bottom line
Main takeaway
PT-141 is bremelanotide, and its approved form, Vyleesi, treats one specific diagnosis: distressing low desire in premenopausal women. The libido peptide for everyone framing is marketing, not the label.
Attach every claim to a product and a population. Vyleesi trial data, the older male intranasal studies, clinic PT-141, and gray-market vials are four different conversations that happen to share a name.
The strongest anchors are the DailyMed label, the FDA approval package, and the RECONNECT phase 3 paper with its open-label extension. Read the 2004 and 2005 male intranasal studies as development history, and the 2008 nonresponder trial with its 2023 expression of concern in view.
Identity
What it is
Bremelanotide is a synthetic cyclic heptapeptide: a ring of seven amino acids that activates melanocortin receptors, mainly MC1R and MC4R at therapeutic doses. The Vyleesi label is unusually honest about the limits of that knowledge: the drug works through this pathway, and the exact mechanism by which it improves HSDD is unknown.
Its origin explains the noise around it. Bremelanotide came out of melanocortin tanning-peptide research, the lineage that also produced Melanotan-2, and it was developed for central sexual effects rather than pigment. The pigment biology never fully left the label, which is why focal hyperpigmentation appears in the warnings.
How it differs from the usual erectile-dysfunction drugs matters for reading the claims. PDE5 inhibitors such as sildenafil act on penile vascular mechanics; bremelanotide acts in the brain on desire pathways. That is why it could be approved for low desire in women, and why calling it a performance drug misreads the evidence.
The male story is development history, not an approval. Intranasal studies from 2004 to 2008 measured erectile responses in men, one small crossover found a stronger response when PT-141 was added to low-dose sildenafil, and the largest trial's paper now carries an expression of concern. No male formulation was approved, and the sprays and vials sold today are not those study products.
How people talk about it online
Forum PT-141 talk is unusually concrete for a peptide market: timing the dose before sex, whether 1 or 2 mg is enough, how bad the nausea gets, injections versus nasal sprays. Much of it quietly borrows the Vyleesi schedule, which is the one part of this market with real documentation behind it.
The other half of the discussion is extrapolation: male libido stacks, confidence and performance marketing, couples' wellness copy. The label says the drug is not indicated for men or for performance enhancement, and the phase 3 program never showed a gain in satisfying sexual events, so all of that runs ahead of the data.
The line to hold is practical. Vyleesi has a labeled dose, timing, monthly cap, and a trial program; everything else sold as PT-141 (vials, sprays, oral products, melanotan-family bundles) needs its own evidence for identity, dose, and route, and does not have it.
Use context
Routes, doses, and cycle patterns
The documented use pattern comes from the Vyleesi label and trial program. It gives product-specific dose, timing, repeat-use, and discontinuation limits for the approved HSDD product. Those details belong to that product, not to non-approved PT-141 vials, nasal products, oral products, or other populations.
Human studies and product labels
Current Vyleesi label
- Purpose
- Acquired, generalized HSDD in premenopausal women
- Context
- FDA label / DailyMed prescribing information
- Route
- Subcutaneous autoinjector per label
- Amount
- 1.75 mg / 0.3 mL
- Frequency
- As needed; not more than one dose within 24 hours
- Duration
- Discontinue after 8 weeks if symptoms do not improve
The label timing is at least 45 minutes before anticipated sexual activity. More than 8 doses per month is not recommended, partly because more frequent use increases focal hyperpigmentation and blood-pressure exposure concerns.
RECONNECT phase 3 core trials
- Purpose
- Sexual desire and distress endpoints in acquired generalized HSDD
- Context
- Two 24-week randomized, double-blind, placebo-controlled trials
- Route
- Subcutaneous autoinjector
- Amount
- 1.75 mg
- Frequency
- As needed before anticipated sexual activity; most patients used two to three doses per month
- Duration
- 24-week double-blind treatment period
The trials measured FSFI Desire and FSDS-DAO distress endpoints. The label reports statistically significant improvement on those co-primary endpoints, while satisfying sexual events did not significantly differ from placebo.
Open-label extension
- Purpose
- Longer follow-up after the double-blind HSDD trials
- Context
- 52-week uncontrolled extension after the core trials
- Route
- Subcutaneous autoinjector
- Amount
- 1.75 mg
- Frequency
- Median 12 injections during the extension phase in the label summary
- Duration
- 52-week open-label extension
This adds longer follow-up context for tolerability and symptom measures, but it is uncontrolled and still tied to the Vyleesi HSDD population.
Intranasal PT-141 erectile-response studies
- Purpose
- Erectile response in healthy men and men with mild-to-moderate erectile dysfunction
- Context
- Double-blind, placebo-controlled early clinical studies
- Route
- Intranasal study formulation
- Amount
- Doses above 7 mg produced a statistically significant response versus placebo
- Frequency
- Single-dose pharmacokinetic and erectile-response assessments
- Duration
- Erectile response monitored after dosing; first erection began at about 30 minutes
The report found significant erectile response versus placebo in healthy men and Viagra-responsive men with erectile dysfunction. Flushing and nausea were the most common adverse events. This was an older intranasal development product, not Vyleesi and not proof of equivalence for current compounded nasal sprays or injections.
Intranasal PT-141 plus sildenafil crossover
- Purpose
- Erectile response when low doses of PT-141 and sildenafil were combined
- Context
- Randomized crossover study in 19 men with erectile dysfunction who reported responding to Viagra or Levitra
- Route
- Intranasal PT-141 with oral sildenafil
- Amount
- 7.5 mg intranasal PT-141 plus 25 mg sildenafil
- Frequency
- Each participant received combination, sildenafil-plus-placebo, and double-placebo conditions
- Duration
- Erectile activity assessed during a 6-hour post-dose period
The combination produced a significantly greater RigiScan erectile response than 25 mg sildenafil alone. The small study supports a combination signal, not a routine regimen, current approval, or equivalence for marketed combination products.
Intranasal bremelanotide in sildenafil nonresponders
- Purpose
- Erectile-function outcomes after prior sildenafil nonresponse
- Context
- Randomized, double-blind, placebo-controlled home-use study in 342 men
- Route
- Intranasal study spray
- Amount
- 10 mg intranasal bremelanotide
- Frequency
- At least 16 attempts, used 45 minutes to 2 hours before sexual stimulation
- Duration
- Outcomes assessed every four attempts and at study end
The report described more positive clinical results and greater intercourse satisfaction with bremelanotide than placebo, along with more drug-related adverse effects. PubMed links a 2023 expression of concern to this article, which materially limits confidence in the result.
Real-world discussion
Community as-needed protocols
- Purpose
- Sexual-function discussion
- Context
- Clinics, forums, and vendor listings
- Route
- Subcutaneous injection, with intranasal sprays also marketed
- Amount
- Commonly described around 1 to 2 mg taken at least 45 minutes to a few hours before activity, mirroring the approved bremelanotide label pattern.
- Frequency
- As needed, with the label pattern limiting use to roughly 8 doses per month
- Duration
- Episodic rather than cycled in most descriptions
PT-141 is the same molecule as approved Vyleesi, so its real-world schedule is unusually well anchored, but gray-market vials are not the approved product, and nausea was common enough in trials to matter. Reported as context, not a recommendation.
What varies
- Population: the best-supported evidence is premenopausal women with acquired, generalized HSDD.
- Goal: the Vyleesi endpoint is low desire and distress, not erections, orgasm, relationship satisfaction, or event count.
- Route: the approved product is subcutaneous autoinjector use; nasal, oral, and vial products need their own evidence.
- Amount: 1.75 mg / 0.3 mL is the Vyleesi label amount, not a universal PT-141 dose.
- Frequency: most phase 3 patients used it two to three times per month; more than 8 monthly doses is not recommended in the label.
- Product quality: sterile autoinjector controls are specific to Vyleesi; gray-market vials and sprays need their own sterility, potency, and delivered-dose documentation.
Human data
Human evidence
By peptide standards the human record is unusually strong; by drug standards it is specific. Two 24-week randomized trials in premenopausal women with acquired, generalized HSDD found statistically significant gains in desire and distress scores over placebo, a 52-week open-label extension adds tolerability follow-up, and the same label reports no significant difference in satisfying sexual events. Separately, controlled intranasal studies from 2004 to 2008 documented erectile responses in men, including a small positive sildenafil-combination crossover, while the largest male trial carries a 2023 expression of concern. Neither record supports bodybuilding, mood, tanning, or generic performance claims, and neither trial product (the autoinjector or the research nasal spray) validates today's compounded vials and sprays.
Evidence maturity
PT-141 has real phase 3 evidence and FDA approval for one narrow HSDD indication; the wider libido and performance market runs past the data.
Bremelanotide emerged from melanocortin tanning-peptide research as a cyclic heptapeptide MC1R and MC4R agonist.
Small double-blind studies from 2004 to 2008 reported erectile responses in men, and one key paper now carries an expression of concern.
Two 24-week randomized trials in premenopausal women with acquired, generalized HSDD improved desire and distress scores versus placebo.
Approved in 2019 as a 1.75 mg as-needed autoinjector for the labeled HSDD population only.
Male use, sexual-performance claims, and compounded vials or nasal sprays sit outside the approved evidence.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Vyleesi FDA label and approval | Premenopausal women with acquired, generalized HSDD | FDA-approved prescribing information and approval documents | Approved Vyleesi 1.75 mg / 0.3 mL single-dose autoinjector | Establishes the approved indication, limitations of use, labeled subcutaneous schedule, contraindications, warnings, drug interactions, and product identity. | Covers the approved Vyleesi setting, not men, postmenopausal women, sexual-performance enhancement, bodybuilding, tanning, wellness programs, or non-approved PT-141 products. | Strong for approved-product facts |
| RECONNECT phase 3 trials | Premenopausal women with acquired, generalized HSDD of at least 6 months duration | Two randomized, double-blind, placebo-controlled 24-week trials | Vyleesi 1.75 mg subcutaneous autoinjector as needed | Improved FSFI Desire and FSDS-DAO distress scores compared with placebo in the label summary and peer-reviewed phase 3 report. | Satisfying sexual events did not significantly differ from placebo, and the trial population does not answer male, postmenopausal, relationship, medication-related, bodybuilding, or wellness claims. | Strong for labeled HSDD endpoints |
| RECONNECT open-label extension | Participants entering longer follow-up after the core HSDD trials | 52-week open-label uncontrolled extension | Vyleesi autoinjector in the same approved-product program | Adds longer follow-up context for safety, tolerability, and symptom measures after the controlled trial phase. | Open-label extension design and continued product/population specificity limit extrapolation to other uses or products. | Moderate supportive follow-up |
| Intranasal PT-141 erectile-response studies | Healthy men and Viagra-responsive men with mild-to-moderate erectile dysfunction | Double-blind, placebo-controlled phase 1 clinical studies | Early intranasal PT-141 development formulation | Erectile response was statistically significant versus placebo at doses above 7 mg, with onset of the first erection at about 30 minutes. Flushing and nausea were the most commonly reported adverse events. | Early studies used instrument-measured erectile response and an intranasal development product. They do not establish current male approval, broad sexual performance benefit, or equivalence for compounded injections or nasal products. | Moderate direct controlled male evidence |
| Intranasal PT-141 plus sildenafil crossover | 19 men with erectile dysfunction who self-reported response to Viagra or Levitra | Randomized three-condition crossover study with visual sexual stimulation | 7.5 mg intranasal PT-141 plus 25 mg oral sildenafil | The combination produced a significantly greater RigiScan erectile response than 25 mg sildenafil alone during the 6-hour assessment. | Small sample, short observation, surrogate erectile-response measurement, and an older intranasal product limit clinical and product-level generalization. | Limited direct controlled combination evidence |
| Intranasal bremelanotide in sildenafil nonresponders | 342 men with erectile dysfunction who did not respond to sildenafil | Randomized, double-blind, placebo-controlled home-use study | 10 mg intranasal bremelanotide before sexual stimulation | The publication reported positive clinical results in 33.5% of evaluable bremelanotide participants versus 8.5% with placebo, with greater intercourse satisfaction and more drug-related adverse effects. | PubMed links a 2023 expression of concern to this publication. That concern, plus the older intranasal formulation, prevents treating the result as dependable proof for current male care or marketed PT-141 products. | Direct controlled evidence with serious publication concern |
| Label safety warnings | Approved-product users and clinical-study participants | Prescribing-information safety synthesis | Vyleesi label and postmarketing safety context | Highlights transient blood-pressure increase with heart-rate reduction, focal hyperpigmentation, nausea, oral-drug absorption issues including naltrexone, pregnancy precautions, and renal or hepatic caution. | Label safety data belong to the approved subcutaneous autoinjector. Compounded, intranasal, oral, research-market, and gray-market products need their own delivered-dose, sterility, and safety evidence. | Strong for label safety context |
Cautions
Safety and unknowns
- Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease, and the label describes transient blood-pressure increases with heart-rate reduction after each dose.
- Nausea is common in the label and phase 3 program; the label reports nausea in 40% of Vyleesi-treated patients and discontinuation due to nausea in 8%.
- Focal hyperpigmentation can occur, including face, gingiva, and breasts, and more frequent dosing increases concern.
- Vyleesi can slow gastric emptying and may affect oral medication absorption; the label specifically warns about reduced exposure to oral naltrexone.
- Pregnancy and lactation require label-specific clinical review. The label advises discontinuation if pregnancy is suspected and contraception for females of reproductive potential while taking Vyleesi.
- Severe renal or hepatic impairment may increase adverse reactions such as nausea and vomiting.
- Safety cannot be inferred for nasal sprays, oral products, compounded supply, research vials, or melanotan-family products from the Vyleesi label.
Product quality
A vial label is only a starting point
Vyleesi is a regulated finished drug: a sterile, clear solution in a prefilled, single-dose autoinjector containing 1.75 mg bremelanotide in 0.3 mL. That is a different product from a loose PT-141 vial, nasal spray, oral product, or clinic-prepared supply.
Product quality claims have to cover identity, concentration, sterility, endotoxin control, excipients, device design, storage, light protection, shipping, adverse-event reporting, and whether the actual delivered route matches the evidence.
Identity
A product name cannot confirm peptide sequence, salt form, potency, impurities, or degradation profile.
Route and formulation
Subcutaneous autoinjector evidence does not tell you the exposure profile for intranasal, oral, compounded, or research-vial products.
Sterility and endotoxin
Injectable products need finished-product controls that a simple purity claim or COA may not establish.
Dose delivery
The Vyleesi dose is a fixed 1.75 mg / 0.3 mL autoinjector; vial reconstitution and nasal sprays can change actual delivered amount.
Storage and handling
The label describes storage at or below 25 C, no freezing, and protection from light; gray-market shipping and storage may not match those conditions.
Mechanism
How it is proposed to work
Bremelanotide activates melanocortin receptors, especially MC1R and MC4R at therapeutic dose levels. That helps explain the sexual-health interest and pigmentation warnings, but the label still says the exact mechanism for improving HSDD in women is unknown.
MC4R-expressing neurons are present in many central nervous system areas, which makes central desire signaling biologically plausible.
MC1R is expressed on melanocytes; activation can increase melanin expression and helps explain focal hyperpigmentation risk.
Bremelanotide is not selective for only one melanocortin receptor subtype, so receptor overlap can create effects and claims outside the desired HSDD endpoint.
Mechanism cannot carry Vyleesi HSDD evidence into male performance, bodybuilding, tanning, mood, or wellness claims.
FAQ
Common questions
Is PT-141 the same thing as Vyleesi?
PT-141 is commonly used as development shorthand for bremelanotide. The approved evidence is Vyleesi, the regulated bremelanotide product for a specific HSDD indication.
Is PT-141 approved for men or sexual performance enhancement?
No. The Vyleesi label states it is not indicated for HSDD in postmenopausal women or in men, and it is not indicated to enhance sexual performance.
Does Vyleesi evidence apply to research-market or melanotan-family products?
No. The evidence is attached to a regulated approved product, its formulation and device, and the studied HSDD population. Non-approved products have separate identity, sterility, labeling, and oversight problems.
Details
Technical details
Sources
References
- 1.
DailyMed. VYLEESI- bremelanotide injection prescribing information 2025.
Accessed 2026-06-09.
Current structured label source for Vyleesi indication, limitations of use, warnings, clinical studies, mechanism, and product identity.
- 2.
FDA. Vyleesi (bremelanotide) subcutaneous injection NDA approval letter 2019.
Accessed 2026-06-09.
FDA approval letter for Vyleesi in premenopausal women with acquired, generalized hypoactive sexual desire disorder.
- 3.
FDA. Vyleesi (bremelanotide) NDA approval package 2019.
Accessed 2026-06-09.
FDA approval package source for application number, approval date, indication, review contents, and regulatory context.
- 4.
PubMed. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials 2019.
doi:10.1097/AOG.0000000000003500 PMID:31599840 Accessed 2026-06-09.
Peer-reviewed RECONNECT randomized phase 3 trial publication in premenopausal women with hypoactive sexual desire disorder.
- 5.
PubMed. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder 2019.
doi:10.1097/AOG.0000000000003514 PMID:31599847 Accessed 2026-06-09.
Open-label extension source for long-term safety and sustained symptom-context evidence after the RECONNECT core phase.
- 6.
Intranasal PT-141 male erectile-response trial. Diamond et al., International Journal of Impotence Research (2004), PMID 14963471.
Direct double-blind placebo-controlled human evidence in healthy men and men with mild-to-moderate erectile dysfunction.
- 7.
Intranasal PT-141 plus sildenafil crossover. Diamond et al., Urology (2005), PMID 15833522.
Direct randomized crossover evidence for erectile response with low-dose intranasal PT-141 plus sildenafil in men with erectile dysfunction.
- 8.
Intranasal bremelanotide in sildenafil nonresponders. Safarinejad and Hosseini, Journal of Urology (2008), PMID 18206919; PubMed links a 2023 expression of concern.
Direct randomized placebo-controlled male erectile-function evidence retained with an explicit expression-of-concern limitation.